LncRNAs in hypoxic microenvironment; insight in their impact in cancer biology
- PMID: 40601072
- DOI: 10.1007/s10142-025-01635-9
LncRNAs in hypoxic microenvironment; insight in their impact in cancer biology
Abstract
Hypoxia may facilitate metastasis and tumor advancement in solid tumors. Intratumoral hypoxia may facilitate tumor aggressiveness by stabilizing hypoxia-inducible factor-1α (HIF-1α). Various transcriptional and epigenetic pathways modulate hypoxia-stimulated gene expression and tumor progression. Noncoding RNAs longer than 200 nt are long noncoding RNAs (lncRNAs). Current lncRNA profiling in several human tumor types revealed that lncRNA expression and deregulation vary by tumor type and may undergo transcriptional, genomic, and epigenetic modifications. LncRNAs controlled by hypoxia have emerged as a prominent focus in hypoxia-regulated biology due to their ability to influence multiple biological procedures associated with tumorigenesis. Hypoxia-regulated lncRNAs may influence tumor development, growth, anti-apoptosis, migration, invasion, angiogenesis, and tumor metabolism. In this light, hypoxia-inducible lncRNAs could interact with protein/protein complex and chromatin/epigenetic factors and another mechanism, thus favoring tumorigenesis. Conversely, lncRNAs may control hypoxia signaling by stabilizing HIF-1α via several mechanisms. Nonetheless, several undiscovered lncRNAs remain that may mediate or regulate the hypoxia axis. Consequently, the novel lncRNAs modulated by hypoxia or that influence hypoxia signaling have yet to be discovered and thoroughly described. Herein, we aim to classify suitable lncRNA targets to offer a feasible therapeutic modality for hypoxia-driven cancers.
Keywords: Cancer; Epigenetics; HIF-1α; Hypoxia; LncRNA.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests. Clinical trial number: Not applicable.
References
-
- Abulihaiti Z, Li W, Yang L, Zhang H, Du A, Tang N et al (2024) Hypoxia-driven lncRNA CTD-2510F5.4: a potential player in hepatocellular carcinoma’s prognostic stratification, cellular behavior, tumor microenvironment, and therapeutic response. Mol Biol Rep 51(1):905 - PubMed
-
- Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heidecke CD et al (2012) Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61(3):439–448 - PubMed
-
- Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N et al (2021) Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M–mutated non–small cell lung cancer previously treated with epidermal growth factor receptor–tyrosine kinase inhibitor: West Japan Oncology Group 8715L Phase 2 randomized clinical trial. JAMA Oncol 7(3):386–394 - PubMed - PMC
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
